Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant

Exclusion Criteria

• •Serious or active medical or psychiatric illness
• •HIV or hepatitis B viral (HBV) infection
• •Stomach disorder that could interfere with the absorption of the study drug
• •Treated with an anti-HCV medication in the last 30 days
• •Any prior exposure to an HCV nonstructural protein (NS)5a-specific inhibitor
• •Use of human granulocyte-macrophage colony-stimulating factor (GM-CSF), epoetin alfa or other therapeutic hematopoietic agents within 2 weeks of screening
• •History of clinically significant medical condition associated with other chronic liver disease
• •Active spontaneous bacterial peritonitis at screening
• •Females who are breastfeeding
• •Infection requiring systemic antibiotics
• •Participated in a clinical study with an investigational drug or biologic within the last 30 days
• •Active or history (last 6 months) of drug or alcohol abuse
• •History of organ transplant other than liver, kidney, or corneal.